Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 1,096 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Vehicle Control Clear all
Completed Phase 2 Interventional Results available

Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery

NCT01666210
View directory record Official record
Conditions
Ocular Inflammation and Pain
Interventions
OTX-DP (Dexamethasone punctum plug), Placebo Vehicle Punctum Plug
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Hoffman Estates, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Oct 20, 2026, 5:07 AM EDT
Completed Phase 3 Interventional

Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis

NCT01878461
View directory record Official record
Conditions
Psoriasis
Interventions
Vehicle, M518101
Drug
Lead sponsor
Maruho North America Inc.
Industry
Eligibility
18 Years and older
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
34
States / cities
Mesa, Arizona • Encino, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2015 · Synced Oct 20, 2026, 5:07 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis

NCT01986920
View directory record Official record
Conditions
Seborrheic Keratosis (SK)
Interventions
A-101 25%, A-101 32.5%, A-101 40%, A-101 Vehicle
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 20, 2026, 5:07 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne

NCT01017120
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene Foam, Vehicle Foam
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years to 45 Years
Enrollment
742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
14
States / cities
Santa Monica, California • Miami, Florida • Alpharetta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Oct 20, 2026, 5:07 AM EDT
Terminated Phase 2 Interventional

Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis

NCT01261403
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
PDA001, Vehicle Controlled Placebo
Biological · Drug
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
16
States / cities
Anniston, Alabama • Arcadia, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Oct 20, 2026, 5:07 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)

NCT05134974
View directory record Official record
Conditions
Mydriasis, Dilation
Interventions
Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophthalmic Solution Vehicle
Drug
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
12 Years and older
Enrollment
368 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
15
States / cities
Newport Beach, California • Westminster, California • Delray Beach, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Oct 20, 2026, 5:07 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model

NCT01332188
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
AC-170 0.05%, AC-170 0.1%, AC-170 0.24%, AC-170 0%
Drug
Lead sponsor
Aciex Therapeutics, Inc.
Industry
Eligibility
10 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Oct 20, 2026, 5:07 AM EDT
Withdrawn Phase 2 Interventional

Study of AGN-190584 Eye Drops to Assess Safety and Efficacy in Participants Aged 40-80 Years With Pseudophakic Presbyopia

NCT05393089
View directory record Official record
Conditions
Presbyopia
Interventions
AGN-190584, Vehicle
Drug
Lead sponsor
Allergan
Industry
Eligibility
40 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
32
States / cities
Dothan, Alabama • Chandler, Arizona • Glendale, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Oct 20, 2026, 5:07 AM EDT
Completed Phase 2 Interventional Results available

Tofacitinib Ointment For Chronic Plaque Psoriasis

NCT01831466
View directory record Official record
Conditions
Psoriasis Vulgaris, Psoriasis
Interventions
tofacitinib ointment 20 mg/g, tofacitinib ointment 10 mg/g, placebo ointment (vehicle)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
476 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
29
States / cities
Hot Springs, Arkansas • Bakersfield, California • Irvine, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Oct 20, 2026, 5:07 AM EDT
Completed Phase 3 Interventional Results available

Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

NCT04211363
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Roflumilast 0.3% cream, Vehicle Cream
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
31
States / cities
Encinitas, California • Fremont, California • Irvine, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Oct 20, 2026, 5:07 AM EDT
Completed Phase 2Phase 3 Interventional Results available

CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

NCT03292809
View directory record Official record
Conditions
Dry Eye Disease
Interventions
CyclASol topical ocular, eye drops, Vehicle topical ocular, eye drops
Drug
Lead sponsor
Novaliq GmbH
Industry
Eligibility
18 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
9
States / cities
Newport Beach, California • Torrance, California • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 20, 2026, 5:07 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Safety of Long-Term Use of Perforomist® (Formoterol Fumarate)

NCT01488019
View directory record Official record
Conditions
COPD
Interventions
Perforomist-Placebo, Perforomist, nebulization, COPD
Drug
Lead sponsor
Dey
Industry
Eligibility
40 Years and older
Enrollment
1,071 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 20, 2026, 5:07 AM EDT
Completed Phase 2 Interventional

A Study of AR-12286 in Patient With Elevated Intraocular Pressure (IOP)

NCT00902200
View directory record Official record
Conditions
Elevated Intraocular Pressure
Interventions
AR-12286, AR-12286 vehicle
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
8
States / cities
Pasadena, California • Petaluma, California • Brooksville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 20, 2026, 5:07 AM EDT
Completed Phase 4 Interventional Results available

A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)

NCT04451330
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Trifarotene cream, Doxycycline hyclate, Trifarotene Vehicle, Doxycycline Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
25
States / cities
Fort Smith, Arkansas • Hot Springs, Arkansas • Rogers, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 20, 2026, 5:07 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis

NCT04475432
View directory record Official record
Conditions
Blepharitis
Interventions
TP-03, 0.25%, TP-03 Vehicle
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
15
States / cities
Phoenix, Arizona • Newport Beach, California • Colorado Springs, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 20, 2026, 5:07 AM EDT
Completed Phase 2 Interventional Results available

Study of AR-13324 in Patients With Elevated Intraocular Pressure

NCT01528787
View directory record Official record
Conditions
Ocular Hypertension, Open Angle Glaucoma
Interventions
AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%, AR-13324 Ophthalmic Solution Vehicle
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
11
States / cities
Newport Beach, California • Fairfield, Connecticut • Roswell, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Oct 20, 2026, 5:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of a Topical Treatment for Dry Age Related Macular Degeneration

NCT01922128
View directory record Official record
Conditions
Nonexudative Age-related Macular Degeneration
Interventions
MC-1101, Placebo
Drug
Lead sponsor
MacuCLEAR, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 20, 2026, 5:07 AM EDT
Completed Phase 1 Interventional

Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

NCT03261739
View directory record Official record
Conditions
NAFLD
Interventions
RYI-018, Placebo
Biological
Lead sponsor
Bird Rock Bio, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Chula Vista, California • Miami, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Oct 20, 2026, 5:07 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of UC-MSCs for COVID-19 Patients

NCT04355728
View directory record Official record
Conditions
Corona Virus Infection, ARDS, ARDS, Human, Acute Respiratory Distress Syndrome, COVID-19
Interventions
Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care., Vehicle + Heparin along with best supportive care
Biological · Other
Lead sponsor
Camillo Ricordi
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Oct 20, 2026, 5:07 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pain and Acetaminophen in Women Study

NCT04573426
View directory record Official record
Conditions
Overweight, Obesity, Healthy Adults
Interventions
Acetaminophen, Placebo, Weight stigma vignette, Control vignette
Drug · Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Oct 20, 2026, 5:07 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Equivalence of Generic Pimecrolimus Cream 1% and Elidel® 1% in Subjects With Mild to Moderate Atopic Dermatitis

NCT02791308
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus Cream 1% (Valeant), Vehicle cream, Pimecrolimus Cream, 1%
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
12 Years to 90 Years
Enrollment
587 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
53
States / cities
Anniston, Alabama • Birmingham, Alabama • Mesa, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated May 29, 2020 · Synced Oct 20, 2026, 5:07 AM EDT
Completed Phase 2 Interventional Results available

Study of CA-008 (Vocacapsaicin) in Bunionectomy Patients

NCT03599089
View directory record Official record
Conditions
Post-surgical Pain
Interventions
CA-008, Placebo, Ketorolac, Acetaminophen, Oxycodone, Bupivacaine Hydrochloride
Drug
Lead sponsor
Concentric Analgesics
Industry
Eligibility
18 Years to 75 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Pasadena, California • Pasadena, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Oct 20, 2026, 5:07 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe Acne

NCT01701024
View directory record Official record
Conditions
Acne
Interventions
ACYC, ACYC vehicle
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
498 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
24
States / cities
Mobile, Alabama • Los Angeles, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Oct 20, 2026, 5:07 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA)

NCT04896385
View directory record Official record
Conditions
Vitiligo
Interventions
Ruxolitinib cream, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
6
States / cities
Fountain Valley, California • Irvine, California • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 20, 2026, 5:07 AM EDT